source
- Novo outlines $23 billion 2035 revenue target, but investors react with a 7% share dropNovo’s chief executive used the recent Capital Markets Day to lay out a long‑term growth plan that targets $23 billion in annual sales by 2035. The strategy emphasizes expanding beyond its flagship…
- Novo acquires three early-stage obesity assets from Kallyope to broaden pipeline amid investor pressureInvestors have been urging Novo to expand its pipeline beyond the semaglutide franchise that drives most of its sales. In response, Novo announced it will acquire three early-stage obesity candida…